<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>102(4)</volume><submitter>Mahalingam D</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumour cell apoptosis by binding to death receptor 4 (DR4) and DR5. DR4 and DR5 activation however can also induce inflammatory and pro-survival signalling. It is not known how these different cellular responses are regulated and what the individual role of DR4 vs DR5 is in these processes.&lt;h4>Methods&lt;/h4>DNA microarray study was carried out to identify genes differentially expressed after DR4 and DR5 activation. RT-PCR and western blotting was used to examine the expression of early growth response gene-1 (Egr-1) and the proteins of the TRAIL signalling pathway. The function of Egr-1 was studied by siRNA-mediated knockdown and overexpression of a dominant-negative version of Egr-1.&lt;h4>Results&lt;/h4>We show that the immediate early gene, Egr-1, regulates TRAIL sensitivity. Egr-1 is constitutively expressed in colon cancer cells and further induced upon activation of DR4 or DR5. Our results also show that DR4 mediates a type II, mitochondrion-dependent apoptotic pathway, whereas DR5 induces a mitochondrion-independent, type I apoptosis in HCT15 colon carcinoma cells. Egr-1 drives c-FLIP expression and the short splice variant of c-FLIP (c-FLIP(S)) specifically inhibits DR5 activation.&lt;h4>Conclusion&lt;/h4>Selective knockdown of c-FLIP(S) sensitises cells to DR5-induced but not DR4-induced apoptosis and Egr-1 exerts an effect as an inhibitor of the DR5-induced apoptotic pathway, possibly by regulating the expression of c-FLIP(S).</pubmed_abstract><journal>British journal of cancer</journal><pagination>754-64</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2837577</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells.</pubmed_title><pmcid>PMC2837577</pmcid><pubmed_authors>Natoni A</pubmed_authors><pubmed_authors>Mahalingam D</pubmed_authors><pubmed_authors>Samali A</pubmed_authors><pubmed_authors>Keane M</pubmed_authors><pubmed_authors>Szegezdi E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells.</name><description>&lt;h4>Background&lt;/h4>Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumour cell apoptosis by binding to death receptor 4 (DR4) and DR5. DR4 and DR5 activation however can also induce inflammatory and pro-survival signalling. It is not known how these different cellular responses are regulated and what the individual role of DR4 vs DR5 is in these processes.&lt;h4>Methods&lt;/h4>DNA microarray study was carried out to identify genes differentially expressed after DR4 and DR5 activation. RT-PCR and western blotting was used to examine the expression of early growth response gene-1 (Egr-1) and the proteins of the TRAIL signalling pathway. The function of Egr-1 was studied by siRNA-mediated knockdown and overexpression of a dominant-negative version of Egr-1.&lt;h4>Results&lt;/h4>We show that the immediate early gene, Egr-1, regulates TRAIL sensitivity. Egr-1 is constitutively expressed in colon cancer cells and further induced upon activation of DR4 or DR5. Our results also show that DR4 mediates a type II, mitochondrion-dependent apoptotic pathway, whereas DR5 induces a mitochondrion-independent, type I apoptosis in HCT15 colon carcinoma cells. Egr-1 drives c-FLIP expression and the short splice variant of c-FLIP (c-FLIP(S)) specifically inhibits DR5 activation.&lt;h4>Conclusion&lt;/h4>Selective knockdown of c-FLIP(S) sensitises cells to DR5-induced but not DR4-induced apoptosis and Egr-1 exerts an effect as an inhibitor of the DR5-induced apoptotic pathway, possibly by regulating the expression of c-FLIP(S).</description><dates><release>2010-01-01T00:00:00Z</release><publication>2010 Feb</publication><modification>2025-04-29T10:30:12.233Z</modification><creation>2019-03-27T00:29:19Z</creation></dates><accession>S-EPMC2837577</accession><cross_references><pubmed>20087343</pubmed><doi>10.1038/sj.bjc.6605545</doi></cross_references></HashMap>